Literature DB >> 18633578

Isolation of cross-reacting antigen candidates by mRNA-display using a mixed cDNA library.

Tatsuro Shibui1, Teruaki Kobayashi, Miwa Shiratori.   

Abstract

The identification of cross-reacting antigens is an important process in the characterization of antibodies. We describe here the application of mRNA-display technology with a cDNA library for the isolation of cross-reacting antigens using a monoclonal antibody against human tumor protein p53 (hTP53) as a model. A mixed cDNA library constructed from mRNAs prepared from several human tissues and cell-lines was used for the mRNA-display. After several rounds of panning, five annotated polypeptides, topoisomeraseII-binding protein 1 (TOBP1), RAS protein activator like 2 isoform 1 (RASAL2), endosome-associated FYVE-domain protein (ZFYVE16), and utrophin (UTRN) as well as hTP53, were identified as cross-reactive antigen candidates. All of them had a consensus motif, -S-D-L-( )-K-L-, which was included in the known epitope of the antibody. They were synthesized in vitro, and their binding was compared by conducting a pull-down assay. In cross-activity to the antibody, they ranked as follows: ZYVE16 congruent with hTP53 congruent with TOBP1 > UTRN > RASAL2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18633578     DOI: 10.1007/s10529-008-9803-5

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  3 in total

1.  In vitro selection of a peptide inhibitor of human IL-6 using mRNA display.

Authors:  Teruaki Kobayashi; Minako Kakui; Tatsuro Shibui; Yasunori Kitano
Journal:  Mol Biotechnol       Date:  2011-06       Impact factor: 2.695

Review 2.  Advantages of mRNA display selections over other selection techniques for investigation of protein-protein interactions.

Authors:  Hui Wang; Rihe Liu
Journal:  Expert Rev Proteomics       Date:  2011-06       Impact factor: 3.940

Review 3.  RASAL2 Plays Inconsistent Roles in Different Cancers.

Authors:  Bolun Zhou; Wei Zhu; Xingjun Jiang; Caiping Ren
Journal:  Front Oncol       Date:  2019-11-13       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.